Kolltan Pharmaceuticals
Antibody Oncology Therapeutics
Kolltan Pharmaceuticals, Inc. develops new generation monoclonal antibody oncology therapeutics. Its products are developed based in receptor tyrosine kinase. The company was founded in 2007 and is based in New Haven, Connecticut.Founded in 2007
Homepage: http://www.kolltan.com
Total money raised: $40M
06511
300 George Street
Suite 530
New Haven
USA CT
Suite 530
New Haven
USA CT
Phone: 203-773-3000
Updated on Apr 23, 2012
Kolltan Pharmaceuticals at CrunchBase
Gerald McMahon President and CEOKolltan Pharmaceuticals at CrunchBase
Arthur Altschul Jr. Co-Founder, Chairman of the Board
Michael Schmertzler Co-Founder
Joseph Schlessinger Co-Founder
Thomas Neff Director
Axel Bolt Director
Past
March, 2012
Kolltan Pharmaceuticals raised $25M in a Series C round
Kolltan Pharma raises $25M in equity offering 
masshightech.com
January, 2010
Kolltan Pharmaceuticals raised $10M in a Series B round
Kolltan Pharmaceuticals Closes $10M Series B Financing 
finsmes.com
October, 2009
Kolltan Pharmaceuticals raised $5M in a Series A round from Purdue Pharma and HBM BioVentures
Kolltan Pharmaceuticals, Inc.: Series A $5M 
onbiovc.com
2007
Kolltan Pharmaceuticals was founded in 2007